Supplementary Online Content

Lin EPY, Hsu CY, Berry L, Bunn P, Shyr Y. Analysis of cancer survival associated with immune checkpoint inhibitors after statistical adjustment: a systematic review and meta-analyses. *JAMA Netw Open*. 2022;5(8):e2227211. doi:10.1001/jamanetworkopen.2022.27211

eMethods. Simulations to Recapture Kaplan-Meier Survival Curves of KEYNOTE-045 and CheckMate 017/057

eFigure 1. Recaptured Kaplan-Meier Curves for KEYNOTE-045 and CheckMate 017/057 by Simulation

eFigure 2. Funnel Plots for Publication Bias of Meta-analyses

eFigure 3. Subgroup Analyses of Overall Survival

eFigure 4. Subgroup Analyses of Progression-Free Survival

eTable. Results of Heterogeneity Tests for Meta-analyses

This supplementary material has been provided by the authors to give readers additional information about their work.
**eMethod: Simulations to recapture Kaplan-Meier survival curves of KEYNOTE 045 and CheckMate 017/057**

eFigure 1 (A) and (B) show survival curves generated from simulated data based on KEYNOTE 045 of chemotherapy ($n_0 = 272$) versus pembrolizumab ($n_1 = 270$) for OS or PFS of patients with advanced UC (1). OS or PFS probabilities at 4-month intervals were extracted from the KM survival curves (Reference 1, Figure 1A-B), and the proportions of long-term responders were assumed to be 0.13 (0.01) and 0.22 (0.11) in the chemotherapy and pembrolizumab arms, respectively. We fitted mixture cure models with Weibull distributions to the extracted probabilities by the nonlinear least-squares method, and we obtained two Weibull distributions with a common shape parameter of 1.133 (0.690) and different scale parameters of 0.697 (0.312) and 0.789 (0.235) for the two arms, respectively. Accordingly, event times were generated from mixture cure models with the estimated Weibull distributions and the proportions of long-term responders. Moreover, we assumed the same uniform distribution $\text{Uniform}(2, 3)$ of censoring time for both arms. Then, we obtained the simulated data and produced the unadjusted KM curves as shown in eFigure 1A-B.

Similarly, eFigure 1 (C) and (D) are simulations from the CheckMate 017/057 trial of docetaxel ($n_0 = 427$) versus nivolumab ($n_1 = 427$) for OS or PFS of patients with advanced NSCLC (2). OS or PFS probabilities at 6-month intervals were extracted from the KM survival curves (Reference 2, Figure 1A for OS and Figure 2A for PFS), and the proportions of long-term responders were assumed to be 0.02 (0.00) and 0.11 (0.07) in the docetaxel and nivolumab arms, respectively. Following the same procedure described as above, we obtained two Weibull distributions with a common shape parameter of 0.939 (0.638) and different scale parameters of 0.931 (0.308) and 1.120 (0.350) for the two arms, respectively. Also, we assumed the same uniform distribution $\text{Uniform}(5, 6.5)$ of censoring time for both arms. Thus, we obtained the simulated data and the unadjusted KM curves as shown in eFigure 1C-D.
eReferences

1. Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970-976.

2. Borghaei H, Gettinger S, Vokes EE, et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021;39(7):723-733.
**eFigure 1.** Recaptured Kaplan-Meier curves for KEYNOTE 045 and CheckMate 017/057 by simulation. KEYNOTE 045 unadjusted and adjusted (A) OS and (B) PFS curves. CheckMate 017/057 unadjusted and adjusted (C) OS and (D) PFS curves. Cox HRs, Cox-TEL HRs and Cox-TEL DPs are shown.
**eFigure 2. Funnel plots for publication bias of meta-analyses.** $p =$ P-value that were obtained from Egger test (Egger) and Begger-Mazumdar test (B-M). The p-values for meta-analysis using only two studies cannot be calculated.
**A**

| StudyReference [year] | Regimen | HR   | ST-HR | LT-OP | Weight (%) |
|-----------------------|---------|------|-------|--------|------------|
| NSCLC | CheckMate 227\(2019\) | Nivo + Ipi vs Platinum doublet | 0.79 (0.67-0.93) | | | 12.9 |
| | KEYNOTE 042\(2017\) | Pembrol vs Platinum doublet | 0.81 (0.73-0.93) | | | 17.5 |
| | Javelin 110\(2021\) | Atezo vs platinum doublet | 0.85 (0.68-1.04) | | | 8.9 |
| | KEYNOTE 130\(2021\) | Atezo + platinum doublet vs platinum doublet | 0.86 (0.71-1.06) | | | 9.2 |
| | CheckMate 067/ST 05\(2021\) | Nivo vs Taasoe | 0.68 (0.58-0.78) | | | 18.6 |
| | OA4\(2021\) | Atezo vs Taasoe | 0.78 (0.68-0.88) | | | 17.5 |
| | KEYNOTE 021\(2021\) | Pembrol vs Taasoe | 0.70 (0.63-0.80) | | | 10.1 |
| | Pooled | 0.77 (0.72-0.82) | | 0.87 (0.82-0.92) | | 1.00 |
| | P-value | <0.001 | | <0.001 | | <0.001 |

**B**

| StudyReference [year] | Regimen | HR   | ST-HR | LT-OP | Weight (%) |
|-----------------------|---------|------|-------|--------|------------|
| UC | KEYNOTE 040\(2018\) | Pembrol vs Taasoe | 0.70 (0.57-0.86) | | | 19.5 |
| | IMpower210\(2021\) | Atezo vs Taasoe/Ipilimumab | 0.82 (0.71-0.94) | | | 60.5 |
| | Pooled | 0.77 (0.66-0.90) | | 0.89 (0.84-1.06) | | 100 |
| | P-value | <0.001 | | 0.490 | | 0.002 |

**C**

| StudyReference [year] | Regimen | HR   | ST-HR | LT-OP | Weight (%) |
|-----------------------|---------|------|-------|--------|------------|
| Melanoma | CA284-004\(2015\) | Ipi + Dac vs Dac | 0.69 (0.57-0.84) | | | 34.8 |
| | CheckMate 662\(2020\) | Nivo vs Dac | 0.50 (0.40-0.63) | | | 33.4 |
| | CheckMate 027\(2017\) | Nivo vs ICC | 0.95 (0.73-1.23) | | | 31.8 |
| | Pooled | 0.69 (0.49-0.96) | | 0.79 (0.52-1.18) | | 100 |
| | P-value | 0.026 | | 0.026 | | 0.024 |

**eFigure 3. Subgroup analyses of overall survival.** (A) NSCLC, (B) UC, (C) melanoma. Forest plots of Cox HRs (HR), Cox-TEL. HRs (ST-HR), and LT-DPs illustrate overall survival endpoints of included studies before and after Cox-TEL adjustment. Individual and pooled HRs, ST-HRs, and LT-DPs are shown with 95% CI. Pooled endpoints are meta-analysis results. The weight for each study is inversely proportional to the within-study variance of log(HR) plus the between-studies variance. Abbreviations: Nivo: nivolumab; Pembrol: pembrolizumab; Atezo: atezolizumab; Ipi: ipilimumab; Dac: dacarbazine; ICC: investigator’s choice chemotherapy (dacarbazine or carboplatin plus paclitaxel).
**Figure 4.** Subgroup analyses of progression-free survival. (A) NSCLC and (B) melanoma. Forest plots of Cox HRs (HR), Cox-TELL HRs (ST-HR), and LT-DPs illustrate progression-free survival endpoints of included studies before and after Cox-TELL adjustment. Individual and pooled HRs, ST-HRs, and LT-DPs are shown with 95% CI. Pooled endpoints are meta-analysis results. The weight for each study is inversely proportional to the within-study variance of log(HR) plus the between-studies variance. Abbreviations: Nivo: nivolumab; Pembro: pembrolizumab; Atezo: atezolizumab; Ipi: ipilimumab; Dac: dacarbazine; ICC: investigator’s choice chemotherapy (dacarbazine or carboplatin plus paclitaxel).
**Table 1. Results of heterogeneity tests for meta-analyses.**

|                | OS     | HR      | ST-HR   | LT-DP   |
|----------------|--------|---------|---------|---------|
|                | CQ-P   | I²      | CQ-P    | I²      |
| **Figure 3 OS**| 0.01   | 58%     | 0.08    | 39%     |
|                |        | (95% CI 20%-78%) |        | (95% CI 0%-69%) |
| **Figure 4 PFS**| <0.01 | 84%     | <0.01   | 87%     |
|                |        | (95% CI 68%-92%) |        | (95% CI 75%-93%) |
| **eFigure 3A**  | 0.27   | 0%      | 0.70    | 0%      |
|                |        | (95% CI 0%-65%) |        | (95% CI 0%-54%) |
| **eFigure 3B**  | 0.20   | -       | 0.03    | -       |
|                |        |         |         |         |
| **eFigure 3C**  | <0.01  | 85%     | 0.83    | 65%     |
|                |        | (95% CI 56%-95%) |        | (95% CI 0%-90%) |
| **eFigure 4A**  | 0.56   | -       | 0.80    | -       |
|                |        |         |         |         |
| **eFigure 4B**  | 0.56   | -       | <0.01   | -       |
|                |        |         |         |         |
| **eFigure 4C**  | <0.01  | 92%     | <0.01   | 91%     |
|                |        | (95% CI 80%-97%) |        | (95% CI 77%-97%) |
|                |        |         |         | <0.01   |
|                |        |         |         | (95% CI 73%-96%) |

CQ-P: Cochran’s Q P-value; I² statistics for meta-analysis using only two studies are not shown.